Indian Journal of Pharmacology Home 

SHORT COMMUNICATION
[View FULLTEXT] [Download PDF]
Year : 2019  |  Volume : 51  |  Issue : 4  |  Page : 276--278

Lurasidone-induced anemia: Is there a need for hematological monitoring?

Vivek C Kirpekar, Abhijeet D Faye, Sudhir H Bhave, Rahul Tadke, Sushil Gawande 
 Department of Psychiatry, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India

Correspondence Address:
Dr. Abhijeet D Faye
Department of Psychiatry (OPD-10), 2nd Floor, OPD Building, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Digdoh Hills, Hingna Road, Nagpur - 440 019, Maharashtra
India

Lurasidone is a newer drug used for treating schizophrenia and depression in bipolar disorder. Although comparatively safe, some side effects can occur with its use such as akathisia, extrapyramidal reaction, metabolic syndrome, and hyperprolactinemia. Blood dyscrasia with lurasidone is rarely reported in the literature except for few case reports. We present two cases of schizophrenia, treated with lurasidone developing anemia after variable period of treatment and reverting after stopping lurasidone. These cases emphasize the timely monitoring of blood parameters for prevention or early detection of anemia in patients treated with lurasidone.


How to cite this article:
Kirpekar VC, Faye AD, Bhave SH, Tadke R, Gawande S. Lurasidone-induced anemia: Is there a need for hematological monitoring?.Indian J Pharmacol 2019;51:276-278


How to cite this URL:
Kirpekar VC, Faye AD, Bhave SH, Tadke R, Gawande S. Lurasidone-induced anemia: Is there a need for hematological monitoring?. Indian J Pharmacol [serial online] 2019 [cited 2021 Sep 25 ];51:276-278
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2019;volume=51;issue=4;spage=276;epage=278;aulast=Kirpekar;type=0